BridgeBio Pharma, Inc. (BBIO) FY2025 10-K Annual Report
BridgeBio Pharma, Inc. (BBIO) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 24, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
BridgeBio Pharma, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Biopharmaceutical development and commercialization with focus on genetic diseases and novel therapies
- • New emphasis on commercialization with FDA approval and US launch of Attruby (net product revenue $362.4M in 2025)
- • Strategic shift: Exclusive EU license of acoramidis to Bayer and sale of royalty rights generating $300M upfront cash
- • Increased SG&A expenses by $242.3M in 2025 supporting commercial launch of Attruby; R&D expenses decreased $54.5M due to program reprioritization
- • Raised $619.3M net from 0.75% convertible notes due 2033 in 2026, used partly for common stock repurchase and refinancing debt
Management Discussion & Analysis
- • No revenue figures or YoY changes disclosed in provided text
- • No profitability or margin percentages reported
- • No segment performance details included
- • No cash flow, buybacks, dividends, or capex figures stated
- • Forward-looking risks and uncertainties highlighted, no specific guidance or outlook provided
Risk Factors
- • Cybersecurity risk managed by multidisciplinary Incident Response Team led by Director of Security with 20 years IT experience
- • Audit Committee oversees enterprise risks, including privacy and cybersecurity, with bi-annual reviews involving legal and executive leadership
- • Board of Directors receives periodic updates on cybersecurity risks and risk management from executive leadership
- • Data Privacy and Security Committee meets quarterly to discuss cybersecurity risk management and reports to Audit Committee
BridgeBio Pharma, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$502M
▲ +126.3% YoY
Net Income
-$725M
▼ -35.3% YoY
Operating Margin
-104.2%
▲ +16297bp YoY
Net Margin
-144.4%
▲ +9705bp YoY
ROE
34.7%
▼ -176bp YoY
Total Assets
$936M
▲ +1.8% YoY
EPS (Diluted)
$-3.78
▼ -31.3% YoY
Operating Cash Flow
-$446M
▲ +14.4% YoY
Source: XBRL data from BridgeBio Pharma, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on BridgeBio Pharma, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.